Menu
Recruiting NCT04123431

ACE Acetabular Cup UK Multi-centre PMCF Study

Observational Hip Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Total Hip Replacement.
Who it may be relevant to
Registry conditions: Hip Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Prospective UK Multi-Centre Post Market Clinical Follow-up Study of the JRI Orthopaedic ACE Acetabular Cup System

Overview

A total hip replacement is one of the most successful and cost-effective surgical procedures in orthopaedics, and involves replacing both the hip ball and socket. Its goal is to provide pain relief, allowing the person to return to a normal lifestyle. JRI Orthopaedics have developed the ACE Acetabular Cup System, which has a H-A.C. coating to promote ossoeintegration of the device within the host bone. To increase the surgeons choice and thus suitability for the patient, there is the option of 3 different socket liners (ceramic, polymer or dual mobility). To ensure maximum safety and performance of medical devices surveillance of the device should be carried out over the devices lifetime. This study is a 10 year surveillance study to assess the clinical, functional and radiological outcomes of the CE-marked ACE Acetabular Cup System. This is done by examining patient outcomes through questionnaires, reviews of X-rays and complications by patients who have received a total hip replacement using the ACE Acetabular Cup System at participating sites.

Interventions

  • Device Total Hip Replacement
    Primary elective total hip replacement

Primary outcome measures

  • Oxford Hip Score [Time frame: 3 years post-op]
Secondary outcome measures (5)
  • Implant Survivorship [Time frame: 6 months, 1 year, 3 years, 5 years, 7 years and 10 years post-op]
  • Oxford Hip Score [Time frame: 6 months, 1 year, 5 years, 7 years and 10 years post-op]
  • Modified Harris Hip Score [Time frame: 6 months, 1 year, 3 years, 5 years, 7 years and 10 years post-op]
  • EQ-5D-5L [Time frame: 6 months, 1 year, 3 years, 5 years, 7 years and 10 years post-op]
  • Radiological Assessment [Time frame: 1 year, 5 years and 10 years post-op]

Eligibility criteria

Inclusion criteria

  • Patients deemed suitable for elective primary THR, as per indications in the IFU.
  • Male or female, 18 years or older.

Exclusion criteria

  • Patients who are unable to provide written informed consent.
  • Patients deemed unsuitable for THR, as per contra-indications in the IFU.
  • Patients indicated for THR as a result of trauma (i.e. neck of femur fracture).
  • Patients who are pregnant (exclusion criteria for THR in general).
  • Patients receiving implants other than the approved combination, i.e. an ACE Acetabular Cup System with a JRI femoral stem and head.
  • Patients who are unable to comply with the protocol.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United Kingdom · 1 center
  • University Hospitals Sussex NHS Foundation Trust — Worthing

Identifiers

NCT: NCT04123431 · JRI-CS-010

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗